Future antithrombotic trials

Cross-source consensus on Future antithrombotic trials from 1 sources and 4 claims.

1 sources · 4 claims

Uses

Dabi-SNAP deliberately restricts enrollment to current DOAC users to avoid adding anticoagulation-related bleeding risk to patients who would not otherwise receive anticoagulation. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
A parallel SNAP domain will compare aspirin and clopidogrel in SAB patients with an independent antiplatelet indication. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
A positive Dabi-SNAP result would support dabigatran as the preferred DOAC for SAB patients who require anticoagulation. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
A later de novo initiation trial could test whether dabigatran should be added to standard care for all SAB patients regardless of prior anticoagulation. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial